Kiniksa Pharmaceuticals International PLC Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
-
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
-
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
-
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
-
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
Trading Information
- Previous Close Price
- $25.47
- Day Range
- $24.50–25.82
- 52-Week Range
- $14.12–27.92
- Bid/Ask
- $18.00 / $27.98
- Market Cap
- $1.75 Bil
- Volume/Avg
- 294,033 / 476,790
Key Statistics
- Price/Earnings (Normalized)
- 222.89
- Price/Sales
- 5.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.18%
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 297
- Website
- https://www.kiniksa.com
Comparables
Valuation
|
Metric
|
KNSA
|
AZN
|
SMMT
|
|---|---|---|---|
Price/Earnings (Normalized) | 222.89 | 20.83 | — |
Price/Book Value | 4.01 | 5.93 | 72.55 |
Price/Sales | 5.18 | 4.78 | — |
Price/Cash Flow | 71.00 | 22.16 | — |
Price/Earnings
KNSA
AZN
SMMT
Financial Strength
|
Metric
|
KNSA
|
AZN
|
SMMT
|
|---|---|---|---|
Quick Ratio | 2.84 | 0.69 | 2.33 |
Current Ratio | 3.57 | 0.89 | 2.35 |
Interest Coverage | — | 5.45 | −13.06 |
Quick Ratio
KNSA
AZN
SMMT
Profitability
|
Metric
|
KNSA
|
AZN
|
SMMT
|
|---|---|---|---|
Return on Assets (Normalized) | 2.27% | 57.63% | −49.56% |
Return on Equity (Normalized) | 2.73% | 151.23% | −108.87% |
Return on Invested Capital (Normalized) | 2.66% | 84.88% | −51.07% |
Return on Assets
KNSA
AZN
SMMT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Hwxqjxldjn | Vdhk | $87.2 Bil | |||
| Merck KGaA ADR
MKKGY
| Yrvbhpbmh | Jxddjqc | $75.7 Bil | |||
| Haleon PLC ADR
HLN
| Nhlqlswz | Zqll | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Xjmstnvg | Tvb | $20.0 Bil | |||
| Viatris Inc
VTRS
| Gxjlrbb | Vdz | $13.7 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Ndjmzqtj | Rxwb | $13.4 Bil | |||
| Catalent Inc
CTLT
| Msfxhpm | Tmwgxhm | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Wymdccqy | Xgqdh | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Ctfgvgm | Dryx | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Swkhtklhx | Hqw | $2.4 Bil |
United States